BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16361982)

  • 1. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW; Clarson CL; Eugster EA; Kemp SF; Radovick S; Rogol AD; Wilson TA;
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative indications for bisphosphonate therapy.
    Landesberg R; Eisig S; Fennoy I; Siris E
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents.
    Simm PJ; Biggin A; Zacharin MR; Rodda CP; Tham E; Siafarikas A; Jefferies C; Hofman PL; Jensen DE; Woodhead H; Brown J; Wheeler BJ; Brookes D; Lafferty A; Munns CF;
    J Paediatr Child Health; 2018 Mar; 54(3):223-233. PubMed ID: 29504223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged bisphosphonate release after treatment in children.
    Papapoulos SE; Cremers SC
    N Engl J Med; 2007 Mar; 356(10):1075-6. PubMed ID: 17347467
    [No Abstract]   [Full Text] [Related]  

  • 11. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series.
    Schwartz S; Joseph C; Iera D; Vu DD
    J Can Dent Assoc; 2008; 74(6):537-42. PubMed ID: 18644240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteogenesis imperfecta, current and future medical treatment.
    Rauch F; Glorieux FH
    Am J Med Genet C Semin Med Genet; 2005 Nov; 139C(1):31-7. PubMed ID: 16278881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.
    Drake MT; Cremers SC
    Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate use in conditions other than osteoporosis.
    Silverman SL
    Ann N Y Acad Sci; 2011 Feb; 1218():33-7. PubMed ID: 20946575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ; Little DG; Briody JN; McEvoy A; Smith NC; Eisman JA; Gardiner EM
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate therapy for fibrous dysplasia.
    DiMeglio LA
    Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.